TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28559862

Group type: EXPERIMENTAL
Intervention: Experimental treatment (EXP) - Treatment as Usual plus Cognitive Behavioral Therapy for psychosis, Family Intervention for psychosis, and Case Management.
Number of subjects: 260

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) - Personalized outpatient psychopharmacological treatment and non-specific supportive clinical management.
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Experimental treatment (EXP) - Family Intervention for psychosis.
Number of subjects: 260

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) - No specific family intervention.
Number of subjects: 260
Study: 25540274

Group type: EXPERIMENTAL
Intervention: Tdap-IPV followed by HepB dose 1 month later (Group 1, n = 145)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Tdap-IPV and HepB administered simultaneously (Group 2, n = 135)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 280
Study: 23545612

Group type: EXPERIMENTAL
Intervention: Topiramate (1mg/kg/day for 3 days, then increased by 1mg/kg/day every third day up to 6mg/kg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Levetiracetam (10mg/kg/day for 5 days, then increased by 10mg/kg/day every 5 days up to 60mg/kg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Crossover to the other drug after initial treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topiramate or Levetiracetam
Number of subjects: 40
Study: 21762177

Group type: EXPERIMENTAL
Intervention: Intravenous alcohol (targeting 40 mg% in 5 minutes) administered immediately after the Trier Social Stress Test (Alc0, n = 11)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intravenous alcohol (targeting 40 mg% in 5 minutes) administered 30 minutes after the Trier Social Stress Test (Alc30, n = 14)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo administered 30 minutes after the Trier Social Stress Test (Alc0 group)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo administered immediately after the Trier Social Stress Test (Alc30 group)
Number of subjects: 25
Study: 18850350

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Strengthening Programme (PRST), 10-week duration
Number of subjects: 13
Study: 16601576

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (alone or in combination with atenolol)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Candesartan (alone or in combination with felodipine)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide/atenolol group
Number of subjects: 9

Group type: COMPARATOR
Intervention: Candesartan/felodipine group
Number of subjects: 9
Study: 14651725

Group type: EXPERIMENTAL
Intervention: KT3‐671 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KT3‐671 80 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KT3‐671 160 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KT3‐671 (all doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14635321

Group type: EXPERIMENTAL
Intervention: Stress management training
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 92
Study: 8733487

Group type: EXPERIMENTAL
Intervention: Tobramycin administered eight hourly aiming for a peak concentration of 10 mg/l and trough below 2 mg/l (Group A)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Tobramycin administered as two equal 12 hourly doses (Group B)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Comparison of average peak tobramycin levels
Number of subjects: 29

Group type: COMPARATOR
Intervention: Comparison of average trough tobramycin levels
Number of subjects: 29

Group type: COMPARATOR
Intervention: Length of hospital stay, readmission rate, and mortality
Number of subjects: 29
Study: 1444287

Group type: COMPARATOR
Intervention: Didanosine 375 mg alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Didanosine 375 mg with ranitidine 150 mg (ranitidine given 2 h prior)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ranitidine 150 mg alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg with didanosine 375 mg
Number of subjects: 12
Study: 3980378

Group type: EXPERIMENTAL
Intervention: 100% O2
Number of subjects: 6

Group type: COMPARATOR
Intervention: Air
Number of subjects: 6
Study: 31889999

Group type: EXPERIMENTAL
Intervention: Health promotion program designed to improve cardiovascular risk management through empowerment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preliminary feasibility study
Number of subjects: 0
Study: 30068305

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo injection (saline solution)
Number of subjects: 40
Study: 26840904

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) program, twice per week for 12 weeks
Number of subjects: 159
Study: 24214919

Group type: EXPERIMENTAL
Intervention: [(15)O]H2O PET
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: ASL MRI
Number of subjects: 31
Study: 22425913

Group type: EXPERIMENTAL
Intervention: Carboplatin/gemcitabine with eicosanoid modulators (celecoxib, zileuton, or both)
Number of subjects: 88
Study: 19173165

Group type: COMPARATOR
Intervention: PDT alone (Group A)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: IVTA on the same day 1 hour after PDT (Group B)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: IVTA 1 week before PDT (Group C)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Combination therapy (Groups B and C)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 92
Study: 17497463

Group type: EXPERIMENTAL
Intervention: Iron-dextran
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Iron-sucrose
Number of subjects: 60
Study: 15956899

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 42
Study: 12192358

Group type: EXPERIMENTAL
Intervention: Workshop attendees
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control reviewers
Number of subjects: 37
Study: 10690067

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 24
Study: 7594128

Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.58 g/kg per day)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Very-low-protein diet (0.28 g/kg per day) with ketoacid-amino acid supplement (0.28 g/kg per day)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Usual-protein diet (1.30 g/kg per day)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Usual blood pressure level
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Low blood pressure level
Number of subjects: 840
Study: 1789606

Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid (Surgam)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 7031186

Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (EACA), 36 g/day
Number of subjects: 151

Group type: COMPARATOR
Intervention: Tranexamic acid (TEA), 6 g/day
Number of subjects: 151
Study: 31249637

Group type: EXPERIMENTAL
Intervention: Nonclosure of the peritoneum
Number of subjects: 112

Group type: COMPARATOR
Intervention: Closure of the peritoneum
Number of subjects: 112
Study: 29152243

Group type: EXPERIMENTAL
Intervention: Pomegranate extract (PE) capsules for 8 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo capsules for 8 weeks
Number of subjects: 55
Study: 26099205

Group type: EXPERIMENTAL
Intervention: Connective Tissue Manipulation (CTM) with lifestyle advice
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lifestyle advice alone
Number of subjects: 50
Study: 25799722

Group type: EXPERIMENTAL
Intervention: Prolit super (4 capsules daily for 2 months)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (for 2 months)
Number of subjects: 57
Study: 21599709

Group type: EXPERIMENTAL
Intervention: Asking questions to confirm traits of in-group members
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asking questions to confirm traits of out-group members
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testing for negative in-group traits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testing for positive out-group traits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderation effect of in-group identification
Number of subjects: 0
Study: 19042161

Group type: EXPERIMENTAL
Intervention: Galantamine (24 mg/day)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 407
Study: 17313511

Group type: EXPERIMENTAL
Intervention: Lambdacyhalothrin-treated hammock nets (ITHN)
Number of subjects: 924

Group type: COMPARATOR
Intervention: Placebo-treated hammock nets (PTHN)
Number of subjects: 924
Study: 15020161

Group type: EXPERIMENTAL
Intervention: Sterile shunt malfunction group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Functioning shunting systems
Number of subjects: 0
Study: 12269648

Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray, 128 microg once daily
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 9437339

Group type: EXPERIMENTAL
Intervention: Slow, unbuffered (SU)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Slow, buffered (SB)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Rapid, buffered (RB)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Rapid, unbuffered (RU)
Number of subjects: 42
Study: 7814168

Group type: EXPERIMENTAL
Intervention: Trifusal
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control (medically treated unstable angina)
Number of subjects: 276
Study: 2653555

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine hydrochloride 50 mg bd (Kontexin)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride 5 mg tid (Ditropan)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combined treatment (Phenylpropanolamine and Oxybutynin)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 66471

Group type: EXPERIMENTAL
Intervention: High-fibre diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 31743054

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy with temozolomide
Number of subjects: 186
Study: 30957699

Group type: EXPERIMENTAL
Intervention: Electric-motor device at 100% concentric speed (EX1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Electric-motor device at 150% concentric speed (EX2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Conventional flywheel device (FW)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 40
Study: 28069560

Group type: EXPERIMENTAL
Intervention: Internet-based intervention with access to weight gain tracker and diet and physical activity goal-setting tools.
Number of subjects: 1335

Group type: COMPARATOR
Intervention: Control arm (no access to weight gain tracker and goal-setting tools).
Number of subjects: 1335
Study: 26054136

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 60
Study: 24119227

Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium
Number of subjects: 14

Group type: COMPARATOR
Intervention: Other immunosuppressive agents
Number of subjects: 14
Study: 21208594

Group type: EXPERIMENTAL
Intervention: TEAM intervention (depression care management intervention focusing on optimizing antidepressant therapy through patient education, symptom monitoring, adherence promotion, and side-effect management)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: TEAM intervention
Number of subjects: 168
Study: 18952309

Group type: EXPERIMENTAL
Intervention: Radiation with neoadjuvant androgen deprivation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation without neoadjuvant androgen deprivation
Number of subjects: 0
Study: 17197656

Group type: EXPERIMENTAL
Intervention: Community Re‐Entry Module (CRM)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard group psychoeducation
Number of subjects: 103
Study: 14982509

Group type: EXPERIMENTAL
Intervention: Montelukast plus cetirizine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cetirizine only
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Montelukast only
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10900108

Group type: EXPERIMENTAL
Intervention: CROM device for measuring abnormal head postures
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CROM device for assessing limitations of ductions
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CROM device for diplopia field testing
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CROM device for diplopia field testing at one third of a meter vs 6 m
Number of subjects: 39
Study: 9286851

Group type: EXPERIMENTAL
Intervention: mibefradil 100 mg once daily
Number of subjects: 640

Group type: COMPARATOR
Intervention: diltiazem CD 360 mg once daily
Number of subjects: 640

Group type: COMPARATOR
Intervention: nifedipine SR 40 mg twice daily
Number of subjects: 640

Group type: COMPARATOR
Intervention: amlodipine 10 mg once daily
Number of subjects: 640

Group type: COMPARATOR
Intervention: nifedipine GITS 60 mg once daily
Number of subjects: 640
Study: 7870897

Group type: EXPERIMENTAL
Intervention: Higher levels of coffee consumption
Number of subjects: 9003

Group type: EXPERIMENTAL
Intervention: Tea consumption
Number of subjects: 9003

Group type: EXPERIMENTAL
Intervention: Estimated overall caffeine consumption
Number of subjects: 9003

Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 9003
Study: 3490807

Group type: EXPERIMENTAL
Intervention: Intermittent electrical stimulation of the muscles of the legs (external electrodes), performed daily 2 X 30 min during the stimulation period (S)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-stimulation period (NS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Stimulation period (S)
Number of subjects: 10
Study: 29703724

Group type: EXPERIMENTAL
Intervention: CHW-led DSME program
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: CHW+PL
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: CHW-only
Number of subjects: 222

Group type: COMPARATOR
Intervention: EUC
Number of subjects: 222
Study: 27261590

Group type: EXPERIMENTAL
Intervention: Haishengsu (HSS)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 248
Study: 25136358

Group type: EXPERIMENTAL
Intervention: Mobil Diab system (telemedical approach for diabetes management)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 40
Study: 22287122

Group type: EXPERIMENTAL
Intervention: Bilateral subtotal thyroidectomy (BST)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Total thyroidectomy (TT)
Number of subjects: 200
Study: 20723593

Group type: EXPERIMENTAL
Intervention: Liu wei di huang wan (LDW), 12 pills, 0.2 g/pill, twice daily for 14 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Liu wei di huang wan (LDW)
Number of subjects: 12
Study: 18684342

Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 microg
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microg
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1015
Study: 12486426

Group type: EXPERIMENTAL
Intervention: Lisinopril treatment for 6 weeks
Number of subjects: 19694
Study: 9703036

Group type: EXPERIMENTAL
Intervention: Bifocal lenses with a +1.50 D add in a flattop segment
Number of subjects: 82

Group type: COMPARATOR
Intervention: Single-vision spectacle lenses
Number of subjects: 82
Study: 8012860

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS) 4 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 2690558

Group type: EXPERIMENTAL
Intervention: Uppsala technique for internal fixation of femoral neck fractures
Number of subjects: 222

Group type: COMPARATOR
Intervention: von Bahr technique for internal fixation of femoral neck fractures
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Patients without pain at 4 months
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Patients with pain at 4 months
Number of subjects: 222
Study: 4904935

Group type: EXPERIMENTAL
Intervention: clofazimine (Lamprene)
Number of subjects: 24

Group type: COMPARATOR
Intervention: prednisolone
Number of subjects: 24
Study: 31738150

Group type: EXPERIMENTAL
Intervention: Intradermal sterile water (0.5 ml)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Intravenous morphine (0.1 mg/kg plus 0.5 ml of intradermal sterile water)
Number of subjects: 94
Study: 27921276

Group type: EXPERIMENTAL
Intervention: Selumetinib (oral MEK inhibitor)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Selumetinib
Number of subjects: 118
Study: 26155923

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (Flovent HFA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Short acting bronchodilators (Proventil HFA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both inhalers (ICS and bronchodilators)
Number of subjects: 10
Study: 22712609

Group type: COMPARATOR
Intervention: MVI 100
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: MVI 200
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: MVI 150
Number of subjects: 374
Study: 21830508

Group type: EXPERIMENTAL
Intervention: Stress training during flight simulator skill acquisition
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no stress training)
Number of subjects: 30
Study: 19808136

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 600-mg extended-release tablets at doses of 2400, 3600, 4800, or 6000 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 17126771

Group type: EXPERIMENTAL
Intervention: Red wine consumption with a high-fat meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-fat meal without red wine
Number of subjects: 0
Study: 15534239

Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg daily)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 11345514

Group type: EXPERIMENTAL
Intervention: Cognitive orientation to daily occupational performance (CO-OP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current therapeutic approach
Number of subjects: 0
Study: 9013720

Group type: EXPERIMENTAL
Intervention: Treatment with carbetamide and caffeine to induce autotetraploid cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expected probabilities derived from computer simulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of NOR-bearing chromosomes
Number of subjects: 0
Study: 8352671

Group type: EXPERIMENTAL
Intervention: Brain magnetic resonance imaging (MRI)
Number of subjects: 418
Study: 3305185

Group type: EXPERIMENTAL
Intervention: Intravariceal sclerotherapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Paravariceal sclerotherapy
Number of subjects: 54
Study: 30744491

Group type: EXPERIMENTAL
Intervention: Telerehabilitation-based motor imagery training (Tele-MIT) twice a week for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (wait-list group without any additional specific treatment)
Number of subjects: 0
Study: 31535138

Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: EPA supplementation
Number of subjects: 89

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 89
Study: 26057328

Group type: EXPERIMENTAL
Intervention: RGTA (Cacicol20) instilled once a day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Artificial tears (control group)
Number of subjects: 18
Study: 23809977

Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tacks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21355143

Group type: EXPERIMENTAL
Intervention: Acupuncture applied to Baihui (GV 20), Yintang (EX-HN 3), Sishencong (EX-HN 1), Taichong (LR 3) and placebo orally.
Number of subjects: 43

Group type: COMPARATOR
Intervention: Acupuncture applied to non-acupoint spots with shallow needling technique and Fluoxetine taken orally.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Observation group (Acupuncture)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (Fluoxetine)
Number of subjects: 43
Study: 19486853

Group type: EXPERIMENTAL
Intervention: Education/enhanced care
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 21
Study: 16750465

Group type: EXPERIMENTAL
Intervention: Amlodipine orotate (5 mg, doubled to 10 mg QD if SiDBP >= 90 mm Hg after 4 weeks)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Amlodipine besylate (5 mg, doubled to 10 mg QD if SiDBP >= 90 mm Hg after 4 weeks)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Amlodipine orotate
Number of subjects: 109

Group type: COMPARATOR
Intervention: Amlodipine besylate
Number of subjects: 109
Study: 15477565

Group type: EXPERIMENTAL
Intervention: Neuronal cell transplantation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 9
Study: 11323582

Group type: EXPERIMENTAL
Intervention: Band ligation and propranolol (propranolol group)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Band ligation alone (control group)
Number of subjects: 77
Study: 9158883

Group type: EXPERIMENTAL
Intervention: 2.4 mg kg‐1 dolasetron mesylate (1.8 mg kg‐1 dolasetron base) by intravenous administration
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2.4 mg kg‐1 dolasetron mesylate (1.8 mg kg‐1 dolasetron base) by oral administration
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous administration
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral administration
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both intravenous and oral administration
Number of subjects: 24